Kinase Pathway Targeted Therapeutics

Kinase Pathway Targeted Therapeutics is organized by Society for Translational Oncology (STO).

Released Date: 4/20/2021
Expires Date: 4/19/2022 

Target Audience:
Physicians who wish to advance their current knowledge of role of BRAF inhibitors in BRAF V600-mutant cancers.

Learning Objectives:
• To enumerate the somatic genetic alterations that result in MAP kinase pathway activation and dependence.
• To summarize supporting the use of BRAF inhibitor-based therapy for BRAF V600 mutant cancers.
• To describe the unique therapeutic strategies currently being investigated in MAP kinase pathway activated tumors outside of BRAF V600 mutations.